N.sup.6 -substituted adenosines
    7.
    发明授权
    N.sup.6 -substituted adenosines 失效
    N6取代的腺苷

    公开(公告)号:US4755594A

    公开(公告)日:1988-07-05

    申请号:US936766

    申请日:1986-12-09

    CPC分类号: C07H19/16

    摘要: The present inventions are novel N.sup.6 -substituted adenosines wherein the N substituent is ##STR1## wherein Ar is an unsubstituted or substituted (1) phenyl, (2) 1- or 2-naphthalenyl, (3) 2- or 3-thienyl, (4) 2- or 3-furanyl, (5) 2-, 4-, or 5-thiazyl, (6) 2-, 3-, or 4-pyridyl, or (7) 2-pyrimidyl wherein the substituents include at least one of lower alkyl, halo, trifluoromethyl, hydroxy, lower alkoxy, lower acyloxyamino, N-lower monoalkyl or N,N-lower dialkylamino, lower thioalkyl, lower alkylsulfonyl, or nitro and R' is hydrogen or alkyl, A is ##STR2## wherein q, q', or q" are one to four, n and m are independently zero to three provided if A is a bond then n and m is at least 2 and if A is other than a bond then n and m is at least one. These novel adenosines have highly desirable central nervous system and cardiovascular activities and therefore the present invention also includes pharmaceutical compositions and methods of use therefor.

    摘要翻译: 本发明是新的N6取代的腺苷,其中N取代基是其中Ar是未取代或取代的(1)苯基,(2)1-或2-萘基,(3)2-或3-噻吩基( 4)2-或3-呋喃基,(5)2-,4-或5-噻唑基,(6)2-,3-或4-吡啶基或(7)2-嘧啶基,其中取代基至少包括 低级烷基,卤素,三氟甲基,羟基,低级烷氧基,低级酰氧基氨基,N-低级单烷基或N,N-低级二烷基氨基,低级硫代烷基,低级烷基磺酰基或硝基,R'是氢或烷基,A是< 其中q,q'或q“为1至4,n和m独立地为0至3,条件是如果A是键,则n和m至少为2,如果A不是键,则n和m是 最后一个。 这些新颖的腺苷具有非常需要的中枢神经系统和心血管活性,因此本发明还包括药物组合物及其用途的方法。

    Mitochondria protecting agents for treating mitochondria associated diseases
    8.
    发明授权
    Mitochondria protecting agents for treating mitochondria associated diseases 失效
    线粒体保护剂用于治疗线粒体相关疾病

    公开(公告)号:US06498191B2

    公开(公告)日:2002-12-24

    申请号:US09733271

    申请日:2000-12-07

    IPC分类号: A61K31225

    摘要: The present invention relates generally to mitochondria protecting agents for treating diseases in which mitochondrial dysfunction leads to tissue degeneration and, more specifically, to compounds, compositions and methods related to the same. The methods of this invention involve administration of a pharmaceutically effective amount of a mitochondria protecting agent to a warm-blooded animal in need thereof, and composition of this invention contain a mitochondria protecting agent in combination with a pharmaceutically acceptable carrier or diluent. Mitochondrial associated diseases which may be treated by the present invention include (but are not limited to) Alzheimer's Disease, diabetes mellitus, Parkinson's Disease, neuronal and cardiac ischemia, Huntington's disease and stroke.

    摘要翻译: 本发明一般涉及用于治疗线粒体功能障碍导致组织变性的线粒体保护剂,更具体地涉及与其相关的化合物,组合物和方法。 本发明的方法涉及向有需要的温血动物施用药学有效量的线粒体保护剂,本发明的组合物含有与药学上可接受的载体或稀释剂组合的线粒体保护剂。 可以通过本发明治疗的线粒体相关疾病包括(但不限于)阿尔茨海默氏病,糖尿病,帕金森病,神经元和心脏缺血,亨廷顿病和中风。